Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$6.92
-0.15 (-2.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $280.1M · quality 86.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.8B
P/E
25.6x
↑EV/EBITDA
12.5x
↑ROE
8.0%
↑Gross Margin
51.9%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.5%
FCF CAGR
+2.6%
FCF margin
22.0%
FCF / Net income
1.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.46B · net income $219.3M · FCF $320.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.46B | $1.46B | $1.40B | $1.51B | $1.57B |
| Net Income | $219.3M | $219.3M | $212.7M | $247.7M | $212.2M |
| EBITDA | $384.8M | $384.8M | $371.2M | $417.6M | $366.9M |
| EPS | 0.27 | 0.27 | 0.26 | 0.30 | 0.26 |
| Gross Margin | 51.9% | 51.9% | 49.7% | 48.7% | 46.7% |
| Operating Margin | 19.5% | 19.5% | 18.6% | 20.6% | 15.0% |
| Net Margin | 15.0% | 15.0% | 15.2% | 16.4% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Current Ratio | 5.54 | 5.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $320.5M | $320.5M | $280.1M | $262.9M | $296.8M |
| Returns | |||||
| ROE | 8.0% | 8.0% | 8.2% | 10.1% | 8.8% |
| Valuation | |||||
| P/E | 25.63 | 25.63 | 28.83 | 28.57 | 46.68 |
| EV/EBITDA | 12.51 | 12.51 | 13.82 | 14.79 | 24.52 |
| P/B | 2.06 | 2.06 | 2.37 | 2.89 | 4.13 |
| Growth & Yield | |||||
| Revenue Growth | 4.1% | 4.1% | -7.3% | -3.9% | — |
| EPS Growth | 2.5% | 2.5% | -14.1% | 16.7% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.9%
EPS terminal req.
$0.61
Spread vs growth
-29.3%
5Y implied EPS CAGR
22.6%
EPS terminal req.
$0.74
Spread vs growth
-20.1%
10Y implied EPS CAGR
16.1%
EPS terminal req.
$1.20
Spread vs growth
-13.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.3%
Start / end P/E
28.7x → 25.8x
EPS bridge
0.26 → 0.27
Residual
-0.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.